← Eichor
Study identifier: NCT07196696 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II)

Condition: Supraglottic Airway Device  ·  Sponsor: Zhejiang Cancer Hospital

PhaseNA
Planned participants9
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Laryngeal masks are core devices for supraglottic airway management, and the accuracy of their anatomical position directly impacts ventilation safety and the incidence of complications. Despite their wide clinical application, gaps remain in understanding their in vivo anatomical characteristics. This study aims to evaluate the in vivo anatomical features (e.g., insertion depth, anatomical alignment, tissue compression) of three laryngeal masks (LMA Supreme, I-gel, GMA-Tulip) using CT scanning in anesthetized patients undergoing CT interventional therapy, providing anatomical evidence for optimized laryngeal mask selection and complication prevention.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaochun Jin, M.D  ·  +86 571-88122564  ·  ec@zjcc.org.cn

Jiangling Wang, Dr  ·  wangjl@zjcc.org.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Ethics Committee of Zhejiang Cancer HospitalHangzhou, Zhejiang, ChinaRecruiting
Jiangling WangHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07196696